Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase III

Treatment

Completed

18 and over

Pharmaceutical / Industry

FE200486 CS21
NCT00295750

Trial Description

Summary

The study will be a three-arm, active-control, multi-centre, parallel group study.

Eligibility Criteria

DIAGNOSIS AND MAIN CRITERIA FOR INCLUSION:

Patients, aged 18 years or over, with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.

Baseline testosterone above the lower limit of normal rang. Life expectancy of at least 12 months.

Trial Contact Information

Trial Lead Organizations/Sponsors

Ferring Pharmaceuticals, Incorporated

James Walker, Pharm.D., M.S.

Study Director

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00295750
Information obtained from ClinicalTrials.gov on July 16, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.